Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637232 | 0.81 | DRD3 (0.77) | DRD2DRD3ABCB1HTR7HTR1A | |
| SCHEMBL1795403 | 0.80 | DRD3 (0.49) | DRD2DRD3ABCB1MOGAT2HTR7 | |
| SCHEMBL1797089 | 0.79 | ACACB (0.49) | DRD2DRD3ABCB1HTR7HTR1A | |
| SCHEMBL1794475 | 0.77 | CXCR4 (0.42) | DRD2DRD3ABCB1MOGAT2HRH3 | |
| SCHEMBL1638176 | 0.77 | CXCR4 (0.44) | DRD2DRD3ABCB1MOGAT2HRH3 | |
| SCHEMBL1958049 | 0.75 | DRD2 (0.44) | DRD2DRD3HTR2AHRH3 | |
| SCHEMBL10231923 | 0.74 | HTR7 (0.42) | DRD2DRD3MOGAT2HTR7HTR1A | |
| SCHEMBL12552340 | 0.74 | CXCR4 (0.51) | DRD2DRD3MOGAT2 | |
| SCHEMBL22860596 | 0.74 | DRD2 (0.49) | DRD2DRD3ABCB1MOGAT2HTR7 | |
| SCHEMBL22543810 | 0.72 | DRD2 (0.47) | DRD2DRD3ABCB1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CCR5, CXCL12 | DRD2 1937/4885DRD3 1974/4885ABCB1 437/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | DRD2 1809/4885DRD3 1850/4885ABCB1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.